The invention relates generally to the treatment of mammalian tissue through the process of bulking, and more specifically to the injection of bulking particles into a treatment region of a mammal
Urinary incontinence, vesicourethral reflux, fecal incontinence, and intrinsic sphincter deficiency (ISD), for example, are disorders that have responded to treatments with augmentative materials. Such disorders occur when the resistance to flow of bodily discharges decreases to the point where the resistance can no longer overcome the intra-abdominal pressure. Nearly all procedures developed to restore continence are based on restoring the lost resistance.
Surgical implantation of artificial sphincters has often been employed to treat patients suffering from urinary incontinence. The surgical implantation of the artificial sphincter commonly requires hospitalization, is relatively complex and expensive, and will usually require six to eight weeks of recovery time. Moreover, the procedure may be unsuccessful if the artificial sphincter malfunctions. As a result, additional surgery is required to adjust, repair, or replace the implant.
Urinary incontinence can also be treated using nonsurgical means. A common method to treat patients with urinary incontinence is periurethral injection of a bulking materiaL One such bulking composition is a Teflon® paste known commercially as “Polytef” or “Urethrin.” This paste is comprised of a fifty-fifty (50-50) by weight mixture of a glycerin liquid with Teflon® (polytetrafluoroethylene (PTFE)) brand particles sold by DuPont. The glycerin is biodegradable, however, and over a period of time the glycerin dissipates into the body and is then metabolized or eliminated leaving only about fifty percent (50%) of the injected mixture (i.e., the Teflon® particles) at the injection site. Consequently, to achieve the desired result, the surgeon typically overcompensate for the anticipated loss of bulking material by injecting a significantly larger amount of material than initially required. At the extreme, this overcompensation can lead to complete closure of the urethra, which could put the patient into temporary urinary retention. Additionally, the eventual dissipation of the glycerin complicates the surgeon's ability to visually gauge the appropriate amount of bulking material to inject. To avoid these over-bulking side effects, the surgeon may ultimately not inject enough bulking mixture, leading to the likelihood of a second or even a third procedure to inject additional material.
Further, the particle size in the Teflon® paste bulking material if sufficiently small may allow the particles to migrate to other locations of the body, such as the lungs, brain, etc. Teflon® particles have been known to induce undesirable tissue reaction and form Teflon® induced granulomas in certain individuals.
In addition, the Teflon® paste is typically highly viscous and can only be injected using a hypodermic needle held by an injection assist device. Use of an injection assist device may be required, because a surgeon would likely not have sufficient strength to force the highly viscous Teflon® paste through a needle of any acceptable size.
Two alternatives to the Teflon® paste are a collagen gel and carbon coated zirconium beads. One such commercially available product includes Contigen®, available from CR Bard. The collagen gel is injected in the same manner as the Teflon® paste and forms a fibrous mass of tissue around the augmentation site. This fibrous mass created by the collagen injection, however, also dissipates over time and is eventually eliminated by the patient's body. As a result, additional injections are periodically required.
Yet another bulking procedure includes the injection of swollen hydrogel particles. The swollen hydrogel particles exhibit relatively low injection forces by incorporating low molecular weight water-soluble organic compounds, along with water, in the particles. See, for example, U.S. Pat. Nos. 5,813,411 and 5,902,832 to Van Bladel et al., and U.S. Pat. No. 5,855,615 to Bley et al., the disclosures of which are hereby incorporated herein by reference in their entireties.
Another alternative to the Teflon paste is a hard particle suspension. One such commercially available product is Durasphere® available from Carbon Medical Technologies. These hard particles, for example carbon coated zirconium beads, are injected in a beta-glucan carrier. The beta-glucan is eliminated by the patient's body over time. As a result, additional injections may be required. Furthermore, hard particle suspensions, depending on the size of the particle, may tend not to be easily dispensed without clogging smaller gauge injection needles.
Furthermore, available methods of injecting bulking agents require the placement of a needle at a treatment region, for example, peri-urethrally or transperenially. Assisted by visual aids, the bulking agent is injected into a plurality of locations, causing the urethral lining to coapt. In cases where additional applications of bulking agent are required (e.g., when bulking agents are dissipated within the body), the newly added bulking agent may need to be injected at a higher pressure than the pressure at which the initial bulking agent was injected. The higher pressure requirements for subsequent injections may result from the effect of closing off the treatment region by the initial bulking agent, thereby creating backpressure when attempting to insert additional bulking agent(s). Typically, the bulking agent is injected at multiple locations to cause the uretheal lining to coapt with a higher opening pressure than the patient had prior to injection of the bulking agent.
Bulking agent delivery methods have attempted to address the issue of subsequent injection requirements. One method that has been employed is hydrodissection of tissue in the vicinity of the treatment region, thereby creating tissue voids designed to decrease the injection pressure required when adding additional bulking agent to the voids. Another method used to reduce injection pressures is the Urovive™ device available from American Medical Systems. Urovive™ utilizes a plurality of silicone balloons that are inserted into the treatment region, specifically, the periphery of the sphincter. The balloons are then filled with a hydrogel to effect tissue coaptation.
The invention generally relates to an injectable bulking composition that does not degrade or dissipate in the body, has sufficiently low viscosity such that it is easily administered via injection, and will not migrate from the site of injection, thereby enabling the affected tissue to maintain the desired constriction without causing undesirable side effects. In addition, the invention generally relates to an injection method that reduces the injection pressure required to place the bulking agents.
In one aspect the invention relates to the use of polymeric particles to facilitate bulking in a treatment region of a mammal's body through injection of the particles into the treatment region. The particles are compliant enough to be delivered through a relatively small gauge injection device. Generally, the invention is employed in the treatment of diseases requiring sphincter bulking, e.g., for treating urinary or fecal incontinence; however, the bulking method described herein can also be used for soft tissue bulking for use during, for example, plastic surgery.
In another aspect the invention relates to a bulking agent for medical applications. The bulking agent includes a carrier and a plurality of substantially spherical polyvinyl alcohol particles dispersed within the carrier. The carrier aids the delivery of the substantially spherical polyvinyl alcohol particles to a site to be bulked.
In yet another aspect, the invention relates to a method for bulking mammalian tissue. The method includes the steps of introducing a bulking agent to the mammalian tissue to coapt the mammalian tissue with the bulking agent. The bulking agent includes a carrier and a plurality of substantially spherical polyvinyl alcohol particles dispersed within the carrier. The carrier aids the delivery of the substantially spherical polyvinyl alcohol particles to a site to be bulked.
In various embodiments of the foregoing aspects, the bulking agent comprises a volume. The volume could be, for example, from about 1 ml to about 30 ml, from about 20 ml to about 30 ml, or from about 2 ml to about 16 ml. In additional embodiments, the substantially spherical polyvinyl alcohol particles are sized from about 40 micron to about 1500 microns in diameter, preferably from about 150 micron to about 1100 microns in diameter, and more preferably from about 500 micron to about 900 microns in diameter. Further, the substantially spherical polyvinyl alcohol particles can comprise pores and/or bioreactive agents, such as drugs, proteins, genes, chemo-therapeutic agents, and growth factors. In other embodiments, the substantially spherical polyvinyl alcohol particles can be compressible and/or substantially dimensionally stable.
In additional embodiments, the carrier can be a water-based solution, such as saline solution. In addition, the carrier can include at least one of a lubricant, a biocompatible thickening agent, or a color. Furthermore, the bulking agent can be delivered through a needle and/or a catheter. In one embodiment, the bulking agent is delivered transuretherally. In addition, the bulking agent can be delivered while viewing the tissue to be bulked with a cytoscope.
In still another aspect, the invention relates to an apparatus for bulking mammalian tissue. The apparatus includes a needle defining a lumen, an inflation device adapted to advance through the lumen of the needle, and a bulking agent insertable via the lumen of the needle. The needle is adapted to penetrate the mammalian tissue. The inflation device is disposed adjacent to the mammalian tissue after being advanced through the needle. The inflation device is inflatable and subsequently deflatable to create a void in the mammalian tissue. The bulking agent is inserted to fill at least partially the void in the tissue, the bulking agent coapting the mammalian tissue.
In various embodiments of the foregoing aspect of the invention, the inflation device can include a biocompatible balloon, and/or a color coating for visualization made from at least one of a silicone, an ethylene vinyl alcohol, a polypropylene, a latex rubber, a polyurethane, a polyester, a nylon, or a thermoplastic rubber. Additionally, the inflation device can have a shape selected from the group consisting of substantially round, oval, hemi spherical, spherical, or oblong. In one embodiment, the needle is sized from 16 gauge to 24 gauge, preferably from 18 gauge to 22 gauge.
In additional embodiments, the bulking agent comprises a plurality of polymeric particles and can be injected into the void by a syringe. In one embodiment, the bulking agent includes a carrier and a plurality of substantially spherical polyvinyl alcohol particles dispersed within the carrier. The carrier aids the delivery of the substantially spherical polyvinyl alcohol particles to a site to be bulked. The bulking agent can further include a color.
In yet another aspect, the invention relates to a method for bulking mammalian tissue. The method includes the steps of inserting an inflation device within a portion of a mammal, inflating the inflation device to compress the mammalian tissue surrounding the inflated inflation device, thereby creating a void in the tissue, deflating the inflation device, removing the inflation device from the mammal, and providing a bulking agent to at least partially fill the void, the bulking agent coapting the mammalian tissue.
In various embodiments of this aspect of the invention, the method includes the steps of inserting a needle with a penetration device into the mammalian tissue, removing the penetration device while retaining the inserted needle, and advancing the inflation device through the needle. The needle can be sized from 16 gauge to 24 gauge, preferably 18 gauge to 22 gauge. The method can also include the step of viewing the tissue to be bulked with a cytoscope. In one embodiment, the inflation device can include a biocompatible balloon, and/or a color coating for visualization made from at least one of a silicone, an ethylene vinyl alcohol, a polypropylene, a latex rubber, a polyurethane, a polyester, a nylon and a thermoplastic rubber. Additionally, the inflation device can have a shape selected from the group consisting of substantially round, oval, hemi spherical, spherical, or oblong.
In additional embodiments, the bulking agent comprises a plurality of polymeric particles and can be injected into the void by a syringe. In another embodiment, the substantially spherical polyvinyl alcohol particles are coated, embedded, or filled with a material that will aid the delivery of the particles to a site to be bulked. In one embodiment, the bulking agent includes a carrier and a plurality of substantially spherical polyvinyl alcohol particles dispersed within the carrier. The carrier aids the delivery of the substantially spherical polyvinyl alcohol particles to a site to be bulked. The bulking agent can further include a color.
These and other objects, along, with advantages and features of the present invention, will become apparent through reference to the following description, the accompanying drawings, and the claims. Furthermore, it is to he understood that the features of the various embodiments described herein are not mutually exclusive and can exist in various combinations and permutations.
In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis generally being placed upon illustrating the principles of the invention. In the following description, various embodiments of the present invention are described with reference to the following drawings, in which:
Embodiments of the present invention are described below. The invention is not limited, however, to these embodiments. For example, various embodiments of the invention are described in terms of treating incontinence; however, embodiments of the invention may be used in other applications, such as cosmetic reconstruction.
Referring to
Referring to
Alternatively, referring to
Furthermore, the present invention relates to a bulking agent including substantially spherical polyvinyl alcohol particles used to facilitate bulking in a region of the human body through injection of the particles into the treatment region. The particles are compliant enough to be delivered through a substantially small gauge injection device. In one embodiment, the particles are 50% compressible. This is accomplished through the use of particles that are adapted to compress as they pass through the small gauge injection device. In one embodiment, a 16 to 24 gauge needle is used to dispense the bulking composition without clogging. In other applications, other size needles may be preferred, for example 18-22 gauge.
Filling the space surrounding the urethra/ureter allows the sphincter to be more readily coapted by the patient to maintain continence. Generally, the present invention is employed in the treatment of diseases requiring bulking, e.g., urinary or fecal incontinence. Some examples of conditions that can be treated by way of the present invention include urinary incontinence, vesicourethral reflux, fecal incontinence and intrinsic sphincter deficiency or ISD. However, the bulking method described herein can also be used for soft tissue bulking for use during, for example, plastic surgery.
In greater detail, the method of providing a bulking agent to the human body includes using polymeric particles, such as polyvinyl alcohol, as a bulking agent and injecting the particles into the treatment region of the human body. An advantage of the present invention is that the particles are substantially non-biodegradable, thereby virtually eliminating the need for replenishing the particles to maintain efficacy. A further advantage of the present invention is that the substantially spherical size and shape of the particles allows for close packing of the particles in the treatment space.
In one embodiment, the particles are made of a water and polyvinyl alcohol mixture. For a description of particles contemplated for use with the present invention, see U.S. patent application Ser. Nos. 10/232,265, 10/215,594, 10/116,330, 10/109,966, 10/231,664, the disclosures of which are hereby incorporated by reference herein in their entirety. Generally, water, polyvinyl alcohol, and alginate are combined and pumped through a nozzle under pressure, generating substantially spherically-shaped droplets. The substantially spherically-shaped droplets encounter a solution that promotes cross-linking of the polyvinyl alcohol. Subsequently, the alginate is removed from the outer surface. The result is a substantially spherically-shaped particle that is substantially all polyvinyl alcohol.
To facilitate other treatments, dosages of bio-active agents can be added to the particles. For example, substances, such as drugs, growth factors, proteins, genes, and chemo-therapeutic agents can be added to the particles to enhance localized treatments while still providing significant bulking benefits. The particles themselves are substantially inert in that they do not tend to react with body fluids and/or tissue. For example, many other types of bulking particles swell in use. In contrast thereto, the substantially spherical polyvinyl alcohol particles are substantially dimensionally stable. Some tissue growth on, near, or around the particle surface may occur, but no biological interaction between the tissue and the particles is expected.
In one embodiment, the particles are substantially solid. In a particular embodiment, the particles are substantially spherically-shaped and are sized in a range of about 40 microns to about 1500 microns in diameter, preferably about 150 microns to about 1100 microns in diameter, and more preferably about 500 microns to about 900 microns in diameter. The size of the particles chosen for a particular application will be determined by a number of factors. Smaller particles are easier to inject with a smaller gauge size needle; however, embolization due to migration of the particles is a concern with the smaller particle sizes. The size of the particles used in a particular procedure will include consideration of the procedure employed, disease progression, the degree of degradation of the affected region, patient size, the disposition of the patient, and the preferences and techniques of the doctor performing the procedure. Similarly, such factors must be considered when determining the proper volume of bulking agent to inject into a patient. In one embodiment of the invention, the volume of bulking composition is about 1 ml to about 30 ml, and preferably about 20 ml to about 30 ml. In another embodiment, the volume of bulking composition injected into a patient is about 2 ml to about 16 ml. However, these amounts can vary significantly based on the doctor's determination as to when the target region is sufficiently bulked up.
To vary compressibility, provide for absorption of medications, or for the purpose of incorporating the particles into the surrounding tissue, the porosity of the particles may be modified. These effects, if desired, can be enhanced by increasing pore size. For example, tissue in-growth can be encouraged by increasing pore size. Preferably, pore sizes are within a range of about 4 microns to about 5 microns up to about 30 microns to about 50 microns. In one embodiment, the pores cover up to 80% of the surface area of the particle.
In one embodiment, the bulking particles are injected through a needle. In other embodiments, a cystoscope is used to allow for viewing the injection area. The bulking particles can be supplemented with a contrast agent to enhance their appearance as an aid to the doctor performing the procedure. Other methods of visual enhancement to assist in viewing of the bulking agent can also be employed. Injection of the particles can also be accomplished transuretherally by, for example, using a catheter.
In another embodiment, the method of providing the bulking agent to the human body further includes mixing the bulking particles with a carrier such that the particles are suspended in the carrier, and then injecting the particles-carrier mix into the treatment portion of the human body. The carrier serves as a lubricant for the particles thereby increasing the ease with which the particles move into the body. In another embodiment, the carrier is a saline solution. In other embodiments bio-compatible thickening agents such as alginate, beta-glucan, glycerin, cellulose, or collagen are added to the carrier or serve as the carrier themselves to modify the viscosity of the carrier. By varying the carrier viscosity, proper disbursement of the bulking particles can be accomplished; however, carriers must not be so viscous that their passage through an injection device is inhibited. In yet another embodiment, the carrier may be bio-active, that is the carrier includes an anti-microbial agent, or the like.
The present invention also relates to a method used to dilate tissue within a treatment tissue region to facilitate injection of the bulking agent. The method includes: inserting a needle with a penetration device (e.g., a taper point obtuator or trocar) into the treatment region (e.g., the sphincter region) (
The method and apparatus for carrying out the method in a method to treat urinary incontinence by bulking the urethral tissue is described generally with reference to
A luer hub 402 or fitting, or in one embodiment a female luer hub, may be adapted to the second end of the needle 400, to which a syringe 412, 418 (
The balloon 408 is adapted to advance through a lumen of the needle 400, and an adapter on the balloon 408 provides a means to lock the balloon 408 to the luer hub 402, which in turn adapts to the syringe 412 (
In one embodiment, the balloon is a colored balloon (e.g., blue) to facilitate remote visualization of the procedure and proper placement of the balloon. Alternatively, the balloon could be clear to transparent and the inflation media could be colored, for example, a colored saline solution. The balloon may be semi-compliant or non-compliant. The balloon may be manufactured from any suitable material, for example, a polymer. Some examples of suitable balloon materials include: silicone, ethylene vinyl acetate (EVA), polypropylene, latex rubber, polyurethane, polyester, nylon and thermoplastic rubber. In one embodiment, the balloon is inflated to, for example, about 3 cm to about 5 cm in diameter. The balloon may assume a variety of shapes. Some shapes that may be considered, depending upon the attendant requirements of the procedure, include substantially round, oval, hemi spherical, and oblong. The length of the balloon may vary depending upon the procedure. In one embodiment, the inflated balloon may have a length in the range of, for example, about 3 cm to about 10 cm. Other balloon configurations may be employed, and the types and methods used to employ the most suitable balloon configurations for a particular application of this invention will be obvious to those skilled in the art.
The balloon 408 is then inflated using an inflation device, such as the syringe 412, creating a void in the treatment region (
The balloon 408 is then deflated and removed from the treatment region, resulting in a tissue void 414 where the inflated balloon 408 previously resided (
A syringe or other injection device 418 containing the bulking agent 416 is then affixed to the needle 400 by way of the luer hub 402. The plunger of the syringe 418 is then depressed, thereby injecting the bulking agent 416 into the tissue void 414 (
While the invention has been shown and described with reference to specific embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Having thus described certain embodiments of the present invention, various alterations, modifications, and improvements will be apparent to those of ordinary skill. Such alterations, modifications, and improvements are within the spirit and scope of the invention, and the foregoing description of certain embodiments is not exhaustive or limiting.
This application is a divisional of co-pending U.S. patent application Ser. No. 13/792,346, filed Mar. 11, 2013, which is a divisional of U.S. patent application Ser. No. 12/946,990, filed on Nov. 16, 2010, now U.S. Pat. No. 8,394,400 which is a divisional of Ser. No. 10/459,895, filed Jun. 12, 2003, which claims the benefit of provisional U.S. patent application Ser. No. 60/388,446, which was filed on Jun. 12, 2002, all of which are incorporated by reference in their entireties herein.
Number | Name | Date | Kind |
---|---|---|---|
2609347 | Wilson | Sep 1952 | A |
3663470 | Nishimura et al. | May 1972 | A |
3737398 | Yamaguchi | Jun 1973 | A |
3957933 | Egli et al. | May 1976 | A |
4025686 | Zion | May 1977 | A |
4055377 | Erickson et al. | Oct 1977 | A |
4076640 | Forgensi et al. | Feb 1978 | A |
4098728 | Rosenblatt | Jul 1978 | A |
4110529 | Stoy | Aug 1978 | A |
4191672 | Salome et al. | Mar 1980 | A |
4198318 | Stowell et al. | Apr 1980 | A |
4243794 | White et al. | Jan 1981 | A |
4246208 | Dundas | Jan 1981 | A |
4266030 | Tschang et al. | May 1981 | A |
4268495 | Muxfeldt et al. | May 1981 | A |
4271281 | Kelley et al. | Jun 1981 | A |
4413070 | Rembaum | Nov 1983 | A |
4427794 | Lange et al. | Jan 1984 | A |
4428869 | Munteanu et al. | Jan 1984 | A |
4429062 | Pasztor et al. | Jan 1984 | A |
4442843 | Rasor et al. | Apr 1984 | A |
4444961 | Timm | Apr 1984 | A |
4452773 | Molday | Jun 1984 | A |
4456693 | Welsh | Jun 1984 | A |
4459145 | Elsholz | Jul 1984 | A |
4472552 | Blouin | Sep 1984 | A |
4477255 | Pasztor et al. | Oct 1984 | A |
4492720 | Mosier | Jan 1985 | A |
4522953 | Barby et al. | Jun 1985 | A |
4542178 | Zimmermann et al. | Sep 1985 | A |
4551132 | Pasztor et al. | Nov 1985 | A |
4551436 | Johnson et al. | Nov 1985 | A |
4568559 | Nuwayser et al. | Feb 1986 | A |
4573967 | Hargrove et al. | Mar 1986 | A |
4622362 | Rembaum | Nov 1986 | A |
4623706 | Timm et al. | Nov 1986 | A |
4657756 | Rasor et al. | Apr 1987 | A |
4661137 | Garnier et al. | Apr 1987 | A |
4663358 | Hyon et al. | May 1987 | A |
4671954 | Goldberg et al. | Jun 1987 | A |
4675113 | Graves et al. | Jun 1987 | A |
4678814 | Rembaum | Jul 1987 | A |
4680320 | Uku et al. | Jul 1987 | A |
4681119 | Rasor et al. | Jul 1987 | A |
4742086 | Masamizu et al. | May 1988 | A |
4743507 | Franses et al. | May 1988 | A |
4772635 | Mitschker et al. | Sep 1988 | A |
4773393 | Haber et al. | Sep 1988 | A |
4782097 | Jain et al. | Nov 1988 | A |
4789501 | Day et al. | Dec 1988 | A |
4795741 | Leshchiner et al. | Jan 1989 | A |
4801458 | Hidaka et al. | Jan 1989 | A |
4804366 | Zdeb et al. | Feb 1989 | A |
4819637 | Dormandy, Jr. et al. | Apr 1989 | A |
4822535 | Ekman et al. | Apr 1989 | A |
4833237 | Kawamura et al. | May 1989 | A |
4850978 | Dudar et al. | Jul 1989 | A |
4859711 | Jain et al. | Aug 1989 | A |
4863972 | Itagaki et al. | Sep 1989 | A |
4929400 | Rembaum et al. | May 1990 | A |
4933372 | Feibush et al. | Jun 1990 | A |
4954399 | Tani et al. | Sep 1990 | A |
4981625 | Rhim et al. | Jan 1991 | A |
4990340 | Hidaka et al. | Feb 1991 | A |
4999188 | Solodovnik et al. | Mar 1991 | A |
5007940 | Berg | Apr 1991 | A |
5011677 | Day et al. | Apr 1991 | A |
H915 | Gibbs | May 1991 | H |
5032117 | Motta | Jul 1991 | A |
5034324 | Shinozaki et al. | Jul 1991 | A |
5047438 | Feibush et al. | Sep 1991 | A |
5079274 | Schneider et al. | Jan 1992 | A |
5106903 | Vanderhoff et al. | Apr 1992 | A |
5114421 | Polak | May 1992 | A |
5116387 | Berg | May 1992 | A |
5120349 | Stewart et al. | Jun 1992 | A |
5125892 | Drudik | Jun 1992 | A |
5147631 | Glajch et al. | Sep 1992 | A |
5147937 | Frazza et al. | Sep 1992 | A |
5149543 | Cohen et al. | Sep 1992 | A |
5158573 | Berg | Oct 1992 | A |
5171214 | Kolber et al. | Dec 1992 | A |
5190766 | Ishihara | Mar 1993 | A |
5202352 | Okada et al. | Apr 1993 | A |
5216096 | Hattori et al. | Jun 1993 | A |
5253991 | Yokota et al. | Oct 1993 | A |
5260002 | Wang | Nov 1993 | A |
5288763 | Li et al. | Feb 1994 | A |
5292814 | Bayer et al. | Mar 1994 | A |
5302369 | Day et al. | Apr 1994 | A |
5314974 | Ito et al. | May 1994 | A |
5316774 | Eury et al. | May 1994 | A |
5344452 | Lemperle | Sep 1994 | A |
5344867 | Morgan et al. | Sep 1994 | A |
5354290 | Gross | Oct 1994 | A |
5369133 | Ihm et al. | Nov 1994 | A |
5369163 | Chiou et al. | Nov 1994 | A |
5369710 | Asai | Nov 1994 | A |
5382260 | Dormandy, Jr. et al. | Jan 1995 | A |
5384124 | Courteille et al. | Jan 1995 | A |
5385561 | Cerny | Jan 1995 | A |
5397303 | Sancoff et al. | Mar 1995 | A |
5398851 | Sancoff et al. | Mar 1995 | A |
5403870 | Gross | Apr 1995 | A |
5417982 | Modi | May 1995 | A |
5431174 | Knute | Jul 1995 | A |
5435645 | Faccioli et al. | Jul 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5468801 | Antonelli et al. | Nov 1995 | A |
5476472 | Dormandy, Jr. et al. | Dec 1995 | A |
5484584 | Wallace et al. | Jan 1996 | A |
5490984 | Freed | Feb 1996 | A |
5494682 | Cohen et al. | Feb 1996 | A |
5494940 | Unger et al. | Feb 1996 | A |
5512604 | Demopolis | Apr 1996 | A |
5514090 | Kriesel et al. | May 1996 | A |
5525334 | Ito et al. | Jun 1996 | A |
5534589 | Hager et al. | Jul 1996 | A |
5541031 | Yamashita et al. | Jul 1996 | A |
5542935 | Unger et al. | Aug 1996 | A |
5553741 | Sancoff et al. | Sep 1996 | A |
5556610 | Yan et al. | Sep 1996 | A |
5556931 | Imura et al. | Sep 1996 | A |
5558255 | Sancoff et al. | Sep 1996 | A |
5558822 | Gitman et al. | Sep 1996 | A |
5558856 | Klaveness et al. | Sep 1996 | A |
5559266 | Klaveness et al. | Sep 1996 | A |
5567415 | Porter | Oct 1996 | A |
5569193 | Hofstetter et al. | Oct 1996 | A |
5569449 | Klaveness et al. | Oct 1996 | A |
5569468 | Modi | Oct 1996 | A |
5571182 | Ersek et al. | Nov 1996 | A |
5583162 | Li et al. | Dec 1996 | A |
5585112 | Unger et al. | Dec 1996 | A |
5595821 | Hager et al. | Jan 1997 | A |
5622657 | Takada et al. | Apr 1997 | A |
5635215 | Takahashi et al. | Apr 1997 | A |
5637087 | O'Neil et al. | Jun 1997 | A |
5637215 | Boschetti et al. | Jun 1997 | A |
5639710 | Lo et al. | Jun 1997 | A |
5648095 | Ilium et al. | Jul 1997 | A |
5648100 | Boschetti et al. | Jul 1997 | A |
5650116 | Thompson | Jul 1997 | A |
5651990 | Takada et al. | Jul 1997 | A |
5653922 | Li et al. | Aug 1997 | A |
5657756 | Vrba | Aug 1997 | A |
5681576 | Henry | Oct 1997 | A |
5695480 | Evans et al. | Dec 1997 | A |
5695740 | Porter | Dec 1997 | A |
5701899 | Porter | Dec 1997 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5718884 | Klaveness et al. | Feb 1998 | A |
5723269 | Akagi et al. | Mar 1998 | A |
5725534 | Rasmussen | Mar 1998 | A |
5746734 | Dormandy et al. | May 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5760097 | Li et al. | Jun 1998 | A |
5766147 | Sancoff et al. | Jun 1998 | A |
5770222 | Unger et al. | Jun 1998 | A |
5779668 | Grabenkort | Jul 1998 | A |
5785642 | Wallace et al. | Jul 1998 | A |
5785682 | Grabenkort | Jul 1998 | A |
5792478 | Lawin et al. | Aug 1998 | A |
5795562 | Klaveness et al. | Aug 1998 | A |
5797953 | Tekulve | Aug 1998 | A |
5807323 | Kriesel et al. | Sep 1998 | A |
5813411 | Van Bladel et al. | Sep 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5827502 | Klaveness et al. | Oct 1998 | A |
5827531 | Morrison et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5833361 | Funk | Nov 1998 | A |
5846518 | Yan et al. | Dec 1998 | A |
5855615 | Bley et al. | Jan 1999 | A |
5863957 | Li et al. | Jan 1999 | A |
5876372 | Grabenkort et al. | Mar 1999 | A |
5877224 | Brocchini et al. | Mar 1999 | A |
5885216 | Evans, III et al. | Mar 1999 | A |
5885547 | Gray | Mar 1999 | A |
5891155 | Irie | Apr 1999 | A |
5895411 | Irie | Apr 1999 | A |
5899877 | Leibitzki | May 1999 | A |
5902832 | Van Bladel et al. | May 1999 | A |
5922025 | Hubbard | Jul 1999 | A |
5928626 | Klaveness et al. | Jul 1999 | A |
5951160 | Ronk | Sep 1999 | A |
5959073 | Schlameus et al. | Sep 1999 | A |
6003566 | Thibault et al. | Dec 1999 | A |
6015546 | Sutton et al. | Jan 2000 | A |
6027472 | Kriesel et al. | Feb 2000 | A |
6028066 | Unger | Feb 2000 | A |
6047861 | Vidal et al. | Apr 2000 | A |
6051247 | Hench et al. | Apr 2000 | A |
6059766 | Greff | May 2000 | A |
6060053 | Atala | May 2000 | A |
6063068 | Fowles et al. | May 2000 | A |
6071497 | Steiner et al. | Jun 2000 | A |
6073759 | Lamborne et al. | Jun 2000 | A |
6090925 | Woiszwillo et al. | Jul 2000 | A |
6096344 | Liu et al. | Aug 2000 | A |
6099864 | Morrison et al. | Aug 2000 | A |
6100306 | Li et al. | Aug 2000 | A |
6139963 | Fujii et al. | Oct 2000 | A |
6149623 | Reynolds | Nov 2000 | A |
6162377 | Ghosh et al. | Dec 2000 | A |
6165193 | Greene, Jr. et al. | Dec 2000 | A |
6191193 | Lee et al. | Feb 2001 | B1 |
6214331 | Vanderhoff et al. | Apr 2001 | B1 |
6224630 | Bao et al. | May 2001 | B1 |
6224794 | Amsden et al. | May 2001 | B1 |
6235224 | Mathiowitz et al. | May 2001 | B1 |
6238403 | Greene, Jr. et al. | May 2001 | B1 |
6258338 | Gray | Jul 2001 | B1 |
6261585 | Sefton et al. | Jul 2001 | B1 |
6264861 | Tavernier et al. | Jul 2001 | B1 |
6267154 | Felicelli et al. | Jul 2001 | B1 |
6268053 | Woiszwillo et al. | Jul 2001 | B1 |
6268405 | Yao | Jul 2001 | B1 |
6277392 | Klein | Aug 2001 | B1 |
6291605 | Freeman et al. | Sep 2001 | B1 |
6306418 | Bley | Oct 2001 | B1 |
6315709 | Garibaldi et al. | Nov 2001 | B1 |
6335384 | Evans et al. | Jan 2002 | B1 |
6344182 | Sutton et al. | Feb 2002 | B1 |
6355275 | Klein | Mar 2002 | B1 |
6394965 | Klein | May 2002 | B1 |
6419624 | Burton et al. | Jul 2002 | B1 |
6423332 | Huxel et al. | Jul 2002 | B1 |
6425854 | Galt et al. | Jul 2002 | B1 |
6432437 | Hubbard | Aug 2002 | B1 |
6478775 | Galt et al. | Nov 2002 | B1 |
6537574 | Hubbard | Mar 2003 | B1 |
6548592 | Lang et al. | Apr 2003 | B1 |
6652883 | Goupil et al. | Nov 2003 | B2 |
7094369 | Buiser et al. | Aug 2006 | B2 |
7131997 | Bourne et al. | Nov 2006 | B2 |
7185657 | Johnson et al. | Mar 2007 | B1 |
7611542 | Bourne et al. | Nov 2009 | B2 |
8394400 | Bourne et al. | Mar 2013 | B2 |
8586071 | Bourne et al. | Nov 2013 | B2 |
20010016210 | Mathiowitz et al. | Aug 2001 | A1 |
20010036451 | Goupil et al. | Nov 2001 | A1 |
20010051670 | Goupil et al. | Dec 2001 | A1 |
20020018752 | Krall et al. | Feb 2002 | A1 |
Number | Date | Country |
---|---|---|
100 26 620 | Jul 2002 | DE |
0251695 | Jan 1988 | EP |
0 402 031 | Dec 1990 | EP |
0 470 569 | Feb 1992 | EP |
0 547 530 | Jun 1993 | EP |
0 706 376 | Apr 1996 | EP |
0 730 847 | Sep 1996 | EP |
0 744 940 | Dec 1996 | EP |
0 797 988 | Oct 1997 | EP |
0 826 381 | Mar 1998 | EP |
0 623 012 | Nov 2004 | EP |
59-196738 | Nov 1984 | JP |
62-45637 | Feb 1987 | JP |
4-74117 | Mar 1992 | JP |
6-57012 | Mar 1994 | JP |
9-110678 | Apr 1997 | JP |
9-316271 | Dec 1997 | JP |
10-130329 | May 1998 | JP |
WO9221327 | Dec 1992 | WO |
WO9319702 | Oct 1993 | WO |
WO9410936 | May 1994 | WO |
WO9503036 | Feb 1995 | WO |
WO9522318 | Aug 1995 | WO |
WO9637165 | Nov 1996 | WO |
WO9639464 | Dec 1996 | WO |
WO9804616 | Feb 1998 | WO |
WO9810798 | Mar 1998 | WO |
WO9912577 | Mar 1999 | WO |
WO9957176 | Nov 1999 | WO |
WO0023054 | Apr 2000 | WO |
WO0040259 | Jul 2000 | WO |
WO0071196 | Nov 2000 | WO |
WO0074633 | Dec 2000 | WO |
WO0170291 | Sep 2001 | WO |
WO0211696 | Feb 2002 | WO |
WO0234298 | May 2002 | WO |
WO0234299 | May 2002 | WO |
WO0234300 | May 2002 | WO |
WO0243580 | Jun 2002 | WO |
03082359 | Oct 2003 | WO |
Entry |
---|
Horak, Biomaterials, vol. 7, Issue 3, Published 1986, Abstract. |
Walsh et al. (Role of Angiography and Embolization for Massive Gastroduodenal Hemorrhage, Journal of Gastrointestinal Surgery, pp. 61-66, vol. 3, No. 1, published 1999). |
Contigen® Bard® Collagen Implant website, “Contigen® Implant can provide safe, effective treatment when surgery is not the preferred or recommended therapy,” http://www.bardcontigen.com/physician.htm, 2 pages, (downloaded Jun. 5, 2002). |
PPTI Product Development: Urology Applications website, “Female Stress Urinary Incontinence,” http://www.ppti.com/Market/SUI.html, 3 pages, (downloaded Jun. 5, 2002). |
The Cleveland Clinic website, “Urology News,” Two New Techniques for Incontinence, http://www.clevelandclinic.org/urology/news/incontinence/vol7j.htm, 2 pages, (downloaded Jun. 5, 2002). |
Bachtsi, A.R. et al., “An experimental investigation of Enzyme Release from Poly (vinyl alcohol) crosslinked Microspheres”, J. Microencapsulation, vol. 12, No. 1, pp. 23-35; 1995. |
Barr, J.D., et al., “polyvinyl Alcohol Foam Particles Sizes and Concentrations Injectable through Microcatheters”, JVIR, vol. 9, No. 1, pp. 113-118; 1998. |
Barttinelli, L. et al., “New Class of Poly (vinyl alcohol) Polymers as Column-Chromatography Stationary Phases for Candida Rugosa Lipase Isoforms Separation”, J. Chromatogr A, vol. 753, No. 1, pp. 47-55; 1996. Abstract. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?. |
Berenstein, A. et al., “Catherer and Material Selection for Transarterial Embolization: Technical Considerations. I. Materials”, Radiology, vol. 132, No. 3, pp. 631-639; 1979. |
Berenstein, A. et al., “Microembolization Techniques of Vascular Occlusion: Radiologic, Pathologic, and Clinical Correlation”, AJNR Am I Neuroradiol, vol. 2, No. 3, pp. 261-267; 1981. Abstract, http://www.ncbi.nlm.nih.gov.entrez/query.fcgi?. |
Bruix,J. et al., “Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma; Results of a Randomized, Controlled Trial in a Single Institution”, Hepatology, Jun. 1998, vol. 27, No. 6, pp. 1578-1583. Available Web Site: http://www.hepatitis-central.com/hcv/hcc/embolization/references.html. |
Buhle, Jr., EL, “Re: Hepatic Arterial Embolization”, UCLA Medicine Online, Available Web Site: http://www.meds.com/archive/mol-cancer/1996/msg00128.html Downloaded Jan. 6, 2007. |
Burczak, et al., “Long-term in vivo performance and biocompatinility of poly (vinyl alcohol) hydrogel macrocapsules for hybrid-type artificial pancreas”, Biomaterials, vol. 17, No. 24, pp. 2351-2356, 1996, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcqi?cmd=retrieve&db=pubmed&list_uids=89824 . . . , pp. 1, 02. |
Burczak, et al., “Polymaric materials for biomedical purposes obtained by radiation methods. V. hybrid artificial pancreas”, Polim Med, vol. 24, No. 1-2, pp. 45-55, 1994, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=7915 . . . , pp. 1, 02. |
Choe, et al., “An experimental study of embolic effect according to infusion rate and concentration of suspension in transarterial particulate embolization”, Invest Radiol, vol. 32, No. 5, pp. 260-270, 1997, Abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=9140745&dopt+Abs . . . , pp. 1, 02. |
Chuang, et al., “Experimental Canine Hepatic Artery Embolization with Polyvinyl Alcohol Foam Particles”, Departments of Diagnostic Radiology and Veterinary Medicine, the University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston, Texas, pp. 21-25. 1982. |
Clarian Health Methodist—Indiana Lions Gamma Knife Center, “Arteriovenous Malformation” Available Web Site: http://www.clarian.com/tyhealth/gammaknife/cond_arter.asp Mar. 5, 2003. |
Colombo M, “Treatment of Hepatocellular Carcinoma”, University of Milan, Inst Internal Med, Irccs Maggiore Res Unit Liver, Canc, Firc, via Pace 9 1-20122 Milan, Italy. Source: Journal of Viral Hepatitis, 1997; 4:125-130. Available Web Site: http://www.home.texoma.net/˜moreland/stats/hcc-9.html. |
Derdeyn, et al., “Collagen-coated acrylic microspheres for embolotherapy: in vivo and in vitro characteristic”, American Journal of Neuroradiology, vol. 18, No. 4, pp. 647-653, 1997 abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=9127025&dopt=Abs . . . , pp. 1, 02. |
Derdeyn, et al., “Polyvinyl alcohol particle size and suspension characteristics”, American Journal of Neuroradiology, vol. 16, pp. 1335-1343, 1995. |
DiLuccio et al., “Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers”, Journal of Pharmaceutical Sciences, Jan. 1994, vol. 83, No. 1, pp. 104-106. |
Gander, et al., “Effect of polymeric network structure on drug release from cross-linked poly (vinyl alcohol) micromatrices”, Pharm Res., vol. 6, No. 7, pp. 578-584, 1989, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=25080 . . . , pp. 1, 02. |
Germano, et al., “Histopathological follow-up study of 66 cerebral arteriovenous malformations after therapeutic embolization with polyvinyl alcohol”, J Neurosurg, vol. 76, No. 4, pp. 607-614, 1992, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=15452 . . . , pp. 1, 02. |
Geschwind et al., “Chemoembolization of Liver Tumor in a Rabbit Model: Assessment of Tumor Cell Death with Diffusion-Weightened MR Imaging and Histologic Analysis”, Journal of Vascular and Interventional Radiology, Dec. 2000, vol. 11., No. 10, pp. 1245-1255. |
Gohel, et al., “Formulation designed and optimization of modified-release microspheres of diclofenac sodium”, Drug Dev Ind Pharm, vol. 25, No. 2, pp. 247-251, 1999, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=100653605&dop=A . . . , pp. 1, 02. |
Goodwin, et al., “Overview of embolic agents and their indications”, Eleventh Annual International Symposium on Endovascular Therapy, pp. 303-306, 1999. |
Goodwin, et al., “Preliminary experience with uterine artery embolization for uterine fibroids”, Journal of Vascular and Interventional Radiology, vol. 8, No. 4, pp. 517-526, 1997. |
Grandfils, et al., “Preparation of poly (D,L) lactide microspheres by emulsion solvent evaporation, and their clinical implications as a convenient embolic material”, J Biomed Mater Res, vol. 26, No. 4, pp. 467-479, 1992, abs: http://www.ncbi.nlm.nih.gov/entrez/query. |
Hamada, et al., “Embolization withcellulose porous beads, II: Clinical Trial,” abs: http://www.ojnr.org/content/abstract/17/10/1901?ijkey=R.a2vRMietlXw, pp. 1-2, 02. 1996. |
Horak, et al., “Hydrogels in endovascular embolization. II. Clinical use of spherical particles”, Biomaterials, vol. 7, 1986. |
Huang, et al., “Percutaneous endovascular embolization of intracerebral arteriovenous malformations. Experience in 72 cases”, Chin Med J, vol. 108, No. 6, pp. 413-419, 1995 abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=75552s . . . , pp. 1, 02. |
International Search Report for International Application No. PCT/Us01/06981 (2 pages). |
Jack, et al., “Radiolabeled polyvinyl alcohol particles: a potential agent to monitor embolization procedures”, Int J Rad Appl Instrum B, vol. 13, No. 3, pp. 235-243, 1986, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=37712, pp. 1, 02. |
Joy C, et al., 1991, “Use of Preoperative Embolization in the Treatment of Vascular Metastatic Lesions of the Spine” Available Web Site: http://www.aaos.org/wordhtm/anmeet91/scipro/ppr472.htm. |
Kai, et al., “The utility of the microcrystalline cellulose sphere as a particulate embolic agent: an experimental study”, American Journal of Radiology, vol. 21, No. 6, pp. 1160-1163, 00, or http://www.ajnr.org/cgi/content/full/21/6/1160, 2000, pp. 1-7. |
Kan, et al., “In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat”, Acta Radiologica, vol. 30, pp. 419-425, 1989. |
Kerber, et al., “Polyvinyl Alcohol Foam: Prepackaged Emboli for Therapeutic Embolization”, American Journal Roentgenol, Jun. 1978, vol. 130, pp. 1193-1194. |
Kerber, “Flow-Controlled Therapeutic Embolization: A Physiologic and Safe Technique”, AJR, Mar. 1980, vol. 134, pp. 557-561. |
Kim, et al., “Composite poly(vinyl alcohol) beads for controlled drug delivery”, Pharm Res, vol. 9, No. 1, pp. 10-16, 1992 abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PibMed&list_uids=1589392&dpot=Abs . . . , pp. 1, 02. |
Kurata, et al., “Preoperative embolization for meningiomas using PVA particles”, No Shinkei Geka, vol. 20, No. 4, pp. 367-373, 1992, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=1570057&dopt=Abs . . . , pp. 1, 02. |
Kurosaki, et al., “Evaluation of PVA-Gel Spheres as GI-Transit Time Controlling Oral Drug Delivery System”, Proceedings of the 19th International Symposium on Controlled Release of Bioactive Materials, Jul. 26-31, 1992, Orlando, Florida, pp. 273-274. |
Kusano, et al., “Low-dose particulate polyvinylalcohol embolization in massive small artery intestinal hemorrhage. Experimental and clinical results”, Invest Radiol, vol. 22, No. 5, pp. 338-392, 1987, abs: http://www.ncbi.nlm.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=34963 . . . , pp. 1, 02. |
Labarre, et al., Complement activation by substituted polyacrulamide hydrogels for embolization and implantation, Biomaterials, vol. 23, pp. 2319-2327, 2002. |
Lammer, et al., “Transcatheteral embolization with polyvinyl alcohol-technic and experimental studies,” Rontgenblatter, vol. 36, No. 1, pp. 10-14, 1983, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=6823530&dopt=Abs . . . , pp. 1, 02. |
Latchaw, et al., “Polyvinyl Foam Embolization of Vascular and Neoplastic Lesions of the Head, Neck, and Spine”, Radiology, Jun. 1979, vol. 131, pp. 669-679. |
Leung, et al., “Determinants of Postembolization Syndrome after Hepatic Chemoembolization”, Journal of Vascular and Interventional Radiology, Mar. 2001, vol. 12, No. 3, pp. 320-326. |
Markoff, et al., “Uterine arteriovenous malformation successfully embolized with a liquid polymer, isobutyl 2-cyanoacrylate”, pp. 659-660, 1999. |
Matsumaru, et al., “Embolic materials for endovascular treatment of cerebral lesions,” J Biometer Sci Polym Ed, vol. 8, No. 7, pp. 555-569, 1997, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=91953& . . . , pp. 1, 02. |
Mid-America Interventional Radiological Society, New Treatment for Uterine Fibroids Avoids Surgery: Available Web Site: http://www.mirs.org/fibroids.htm 2003. |
Nakabayashi, et al., “Evaluation of particulate embolic materials with MR imaging, scanning electron microscopy, and phase-contrast microscopy”, American Journal of Neuroradiology, vol. 18, No. 3, pp. 485-491, 1997, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=90904 . . . , pp. 1-2, 02. |
Nakstad, et al., “Embolization of intracranial arteriovenous malformations and fistulas with polyvinyl alcohol particles and platinum fibre coils”, Neuroradiology, vol. 34, No. 4, pp. 348-351, 1992, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=15284 . . . , pp. 1, 02. |
Nash, et al., “Modifications of polystyrenic matrices for the purification of proteins. II. Effect of the degree of glutaraldehyde-poly(vinyl alcohol) crosslinking on various dye ligand chromatography systems”, J. Chromatogr A, vol. 776, No. 1, pp. 55-63, 1997, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=92860 . . . , pp. 1, 02. |
Nikishin LF, et al., 1999, “Interventional radiology in diffuse toxic goiter”, European Congress of Radiology-ECR 1999, Available Web Site: http://www.ecr.org/conference/ecr1999/sciprg/abs/p090041.htm. |
Ophir, et al., “Ultrasonic backscatter from contrast producing collagen microspheres”, Ultrasonic Imaging, vol. 2, pp. 67-77, 1980. |
Oregon Health Sciences University, “Fibroid Embolization”, Available Web Site: http://www.uhmc.edu/dotter-fibroid. Jun. 2001. |
Parker, et al., “A particulate contrast agent with potential for ultrasound imaging of liver”, Ultrasounds in Medicine and Biology, vol. 13, No. 9, pp. 555-566, 1987. |
Pesant A.C., et al., 1997, “Dural fistulas involving the cavernous sinus: Treatment by embolization—7 cases”, European Congress of Radiology—ECR 1997, Available Web Site: http://www.ecr.org/conferences/ecr1997/sciprg/abs/9703008p.htm. |
Physicans' Desk Reference Family Guide to Women's Health, “Chapter 1—Guide to Typical Sympton and Their Meaning”, Available Web Site: http://www.healthsquare.com/pdrfg/wh/chapters/wh1ch01.htm , Pub. Jan. 15, 1994. |
Pritchard, et al., “Poly(vinyl Alcohol): Basic Properties and Uses”, London, England: Gordon and Breach Science Publishers. 1970. |
Pryor J and Berenstein A., Epistaxis(Nose-bleeds), Available Web Site: http://www.wehealny.org/inn/Radiology/nosebleeds.html, Mar. 9, 2001. |
Purdy, et al., “Arteriovenous malformations of the brain: choosing embolic materials to enhance safety and ease of excision”, J Neurosurg., vol. 77, No. 2, pp. 217-222, 1992, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=16250 . . . , pp. 1-2, 02. |
Quisling, et al., “Histopathology analysis of intraarterial polyvinyl alcohol microemboli in rat cerebral cortex”, American Journal of Neuroradiology, vol. 5, pp. 101-104, 1984. |
Rajan, et al., “Sarcomas Metastatic to the liver: Response and Sirvival after Cisplatin, Doxorubicin, Mitomycin-C, Ethiodol, and Polyvinyl Alcohol Chemoembolization”, Journal of Vascular and Interventional Radiology, Feb. 2001, vol. 12, No. 2, pp. 187-193. |
Ramos, et al., “Tumor vascular signals in renal masses: detection with Doppler US”, Radiology, vol. 168, No. 3, pp. 633-637, 1988. |
Shakif, A., “Intraesophageal Polytef injection for the treatment of reflux esophagitis”, Department of Surgery and Experimental Research, Faculty of Medicine, Cairo University, Cairo, Egypt, pp. 1-2, Accepted: Oct. 15, 1994, http://www.ahmedshakif.org/Group-D/d016.htm. |
Spickler, et al., “The MR appearance of endovascular embolic agents in vitro with clinical correlation”, Comput Med Imaging Graph, vol. 14, No. 6, pp. 415-423, 1990, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=21487 . . . , pp. 1, 02. |
Spies JB, “Georgetown University Medical Center. Uterine Fibroid Embolization (UFE). An alternative to surgery for patients with uterine fibroids. Literature Review.” Available Web Site: http://www.dml.georgetown.edu/fibroids, Sep. 1, 2001. |
Strunk, et al., “Treatment of congenital coronary arteriovenous malformations with microparticle embolization”, Cathet Cardiovasc Diagn., vol. 22, No. 2, pp. 133-136, 1991, abs: http://www.ncbi.nim.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=2009563&dopt=Abs . . . , pp. 1, 02. |
Swanson DA et al., 1980, “The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma”, Urologic Clinics of North America 7(3):719-730, 1980. University of Pennsylvania Cancer Center-Oncolink. Available Web Site: http://www.oncolink.upenn.edu/pdg.html/cites/00/00585.html. |
Tabata, et al., “Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection”, Journal of Controlled Release, Jan. 2, 1998, vol. 50, Nos. 1-3, pp. 123-133. |
Tadavarthy, et al., “Polyvinyl Alcohol (Ivalon) as an Embolizing Agent”, The American Journal of Roentgenology Radium Therapy and Nuclear Medicine, Nov. 1975, vol. 125, No. 3, pp. 609-616. |
Tadavarthy, et al., “Polyvinyl Alcohol (Ivalon) as an Embolizing Agent”, Seminars in Interventional Radiology, vol. 1, No. 2, Department of Radiology, University of Minnesota Hospitals, Minneapolis, Minnesota, Jun. 1984, pp. 101-109. 2001. |
Tao, et al., “Study on embolization of hepatitis artery using microspheres”, Acta Pharmaceutica Sinica, vol. 23, No. 1, pp. 55-60; 1988. Translation. |
Terada, et al., “Preoperative embolization of meningiomas fed by ophthalmic branch arteries”, Surg Neurol, vol. 45, No. 2, pp. 161-166, 1996, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=86070 . . . , pp. 1, 02. |
Thanoo, et al., “Controlled release of oral drugs from cross-linked polyvinyl alcohol miscrospheres”, J Pharm Pharmacol, vol. 45, No. 1, pp. 16-20, 1993, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=8094434&dop=Abs . . . , pp. 1, 02. |
Thanoo, et al., “Tantalum loaded silicone microspheres as particulate emboli”, J. Microencapsul, vol. 8, No. 1, pp. 95-101, 1991, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=1880697&dop=Abs . . . , pp. 1, 02. |
The Fibroid Embolization Center of the New York United Hospital Medical Center, “Fibroid Facts”, Available Web Site: http://www.uhmc.com/fibro2.htm, Apr. 29, 1999. |
The Vanderbilt-Ingram Cancer Center, “Kidney Cancer.” Available Web Site: http://www.mc.Vanderbilt.Edu/cancer/cancerinfo/kidney.html, Sep. 18, 2000. |
Tikkakoski, et al., “Preoperative embolization in the management of neck paragangliomas”, Laryngoscope, vol. 107, pp. 821-826, 1997. |
Touho, et al., “Intravascular treatment of spinal arteriovenous malformation using a microcatheter with special reference to serial xylocaine tests and intravascular pressure monitoring”, Surgical Neurology, vol. 42, No. 2, pp. 148-156, 1994, abs: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=PubMed&list_uids=80912 . . . , pp. 1, 02. |
UCLA Radiological Sciences, “A summary of terms appearing in this text.” Available Web Site: http://www.radsci.ucla.edu:8000/aneurysm/terms.html,Aug. 19, 2000. |
University Medical Center SUNY Stony Brook, Department of Urology, “Variocele and its treatment.” Available Web Site: http://www.hsc.sunysb.edu/urology/male_inf...variocele_and_its)treatment.html, Mar. 12, 2001. |
Vivas S., et al., “Arterioportal fistula and hemobilia in a patient with hepatic transplant”, Gastroenterol Hepatol, Feb. 1998;21(2):88-9, Available Web Site: http://www.doyma.es/copiani/revistas/gastro/abstr/abs_p080.html. |
Vogel F., “Nonsurgical Management of Uterine Fibroids”, Available Web Site: http://www.holyname.org/brochure/fibroids.html, Mar. 4, 1998. |
Wakhloo, et al., “Extended preoperative polyvinyl alcohol microembolization of intracranial meningiomas: Assessment of two embolization techniques”, American Journal of Neuroradiology, vol. 14, pp. 571-582, 1993. |
Walker WJ, “Non Surgical Treatment of Fibroids in the UK by Uterine Artery Embolisation—An Alternative to Hysterectomy, Myomectomy, and Myolysis”, Available Web Site: http://www.fibroids.co.uk/thepaper.html, Oct. 19, 1999. |
Wikholm G, et al., 1996, “Embolization of Cerebral Arteriovenous Malformations: Part 1—Technique, Morphology, and Complications”, Departments of Neurology (CL) and Interventional Radiology (GW, PS) Sahlgrenska University Hospital, Goteborg, Sweden. Neurosurgery. Sep. 1996;39(3):448-57;discussion 457-9. Available Web Site: http://www.wwilkins.com/neurosurgery/0148-396X9-96inter.html. |
Worthington-Kirsch RL, 1999, “Interventionalists offer management option for uterine fibroids.” Diagnostic Imaging, pp. 47-49. Available Web Site: http://www.dimag.com/references/9903wortrefs.html. |
Worthington-Kirsch, et al., “Uterine arterial embolization for the management of leiomyomas: Quality-of-life assessment and clinical response”, Radiology, vol. 208, No. 3, 625-629, 1998. |
Yamada, et al., “Extended intraarterial cisplatin infusion for treatment of gynecological cancer after alteration of intrapelvic blood flow and implantation of a vascular access device”, International Radiology, Int'l Radiology 19 1996 139-145. |
Number | Date | Country | |
---|---|---|---|
20140072636 A1 | Mar 2014 | US |
Number | Date | Country | |
---|---|---|---|
60388446 | Jun 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13792346 | Mar 2013 | US |
Child | 14082274 | US | |
Parent | 12946990 | Nov 2010 | US |
Child | 13792346 | US | |
Parent | 10459895 | Jun 2003 | US |
Child | 12946990 | US |